Topic: Vivus Inc.
CHICAGO (Reuters) - An experimental drug that chokes off the blood supply to fat cells helped obese monkeys slim down, a sign that it may work in people, too, U.S. researchers said on Wednesday.The drug, known as Adipotide, takes a different approach ...
VIVUS, Inc. announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug Qnexa (phentermine/topiramate) Controlled-Release Capsules. The FDA requested that VIVUS formally submit ...
Biotech company Arena awaits the Food and Drug Administration's (FDA) approval of Lorcaserin, while Vivus waits for FDA approval of the drug Qnexa, and Orexigen waits for their contender in the obesity war, Contrave, to be approved.. The history of the weight-reduction ...
Just days after denying approval of Arena Pharmaceuticals' (ARNA) lorcaserin to treat obesity, the U.S. Food and Drug Administration notified Vivus (VVUS) it would not approve its application to market its experimental obesity drug Qnexa (phentermine/topiramate) without additional information. Vivus had sought ...
Just days after denying approval of Arena Pharmaceuticals' (ARNA) lorcaserin to treat obesity, the U.S. Food and Drug Administration notified Vivus (VVUS) it would not approve its application to market its experimental obesity drug Qnexa (phentermine/topiramate) without additional information. Vivus had sought ...
FDA's complete response letter on Qnexa was probably the best Vivus (VVUS) could have hoped for. (Vivus sheds more weight after Adcom rejection of Qnexa, July 16, 2010). The only mystery left was what the FDA would ask of Vivus. Instead, the ...
The decision late last week by the FDA to encourage Abbott Laboratories (ABT) to withdraw its Meridia diet pill has obvious implications for other drugmakers seeking approval for obesity drugs. On the other hand, the emphasis on safety - notably cardiovascular safety ...
MO, Oct. 7 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that data on QNEXA , an investigational drug candidate, are highlighted in six poster presentations at the 28th Annual Scientific Meeting of The Obesity Society, being held October 8-12, 2010 in ...
That's the promise of the experimental weight loss drug Qnexa, according to its developer, Vivus (VVUS). Illustrating Qnexa's safety and efficacy to the U.S. Food and Drug Administration is Vivus' top concern as it races to dispel concerns about the drug's risks ...
MO, Sept. 21 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that data on QNEXA(R), an investigational drug candidate, are featured in two poster presentations at the 46th Annual Meeting of the European Association for the Study of Diabetes, being held September ...
From Around the Web
Video Gallery
-
Vivus Down 57% Following US Food ...
Shares of Vivus, Inc. (NASDAQ:VVUS) experienced a staggering 57 ...2010-07-16 -
VIVUS Applies for Market Authorization of ...
VIVUS, Inc. (NASDAQ:VVUS) applied for authorization to market its ...2010-12-20 -
IDIX, BVSN, MDVN, JAZZ - Stock Charts ...
1/09/12 - It was a mixed day on Wall ...2012-01-10
